drugset / Trial / NCT00037544

Study Evaluating ReFacto AF in Severe Hemophilia A

NCT00037544

Treatment

Summary

To characterize the safety and efficacy of ReFacto AF in treating acute bleeding episodes during prophylaxis treatment, including neoantigenicity.

Timeline

Start
Primary completion
2004-08
Completion
2004-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Moroctocog alfa Protein / enzyme biologic

Indications